Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CELLISTEM-OA
- Development stage
- Phase 2
- Lead developer
- Cells for Cells
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
CELLISTEM-OA is an autologous cell therapy product composed of adipose-derived mesenchymal stem cells (AD-MSCs), specifically developed for the treatment of osteoarthritis, particularly of the knee. Developed by the Turkish biotechnology company Cellistem, the treatment involves harvesting a patient's own adipose tissue, followed by the isolation, expansion, and characterization of mesenchymal stem cells in a GMP-certified facility. These cells are then administered via intra-articular injection into the affected joint. The therapeutic effect is mediated through the secretion of various bioactive molecules (paracrine effect) that modulate the inflammatory environment, inhibit pro-inflammatory cytokines, and promote the repair of damaged articular cartilage. It is intended for patients with degenerative joint disease who have not responded to conventional pharmacological or physical therapies.
- Brand names
- CELLISTEM-OA
- Other names
- Autologous adipose-derived mesenchymal stem cellsAD-MSCs
Beyond the preview
Go deeper on CELLISTEM-OA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CELLISTEM-OA.